Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 2:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Bone Mineral Density Clear all
Terminated Phase 4 Interventional Results available

Denosumab in Primary Hyperparathyroidism

NCT01558115
View directory record Official record
Conditions
Primary Hyperparathyroidism
Interventions
Denosumab, Placebo
Drug · Other
Lead sponsor
Columbia University
Other
Eligibility
40 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Jul 23, 2026, 2:45 AM EDT
Completed Phase 2 Interventional

Parathyroid Hormone (PTH) With Alendronate for Osteoporosis

NCT00005006
View directory record Official record
Conditions
Osteoporosis
Interventions
Parathyroid Hormone, Alendronate, Teriparatide
Drug
Lead sponsor
Helen Hayes Hospital
Other
Eligibility
50 Years and older · Female only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1987 – 2006
U.S. locations
1
States / cities
West Haverstraw, New York
Source: ClinicalTrials.gov public record
Updated Aug 18, 2015 · Synced Jul 23, 2026, 2:45 AM EDT
Completed No phase listed Observational

Bone Mineral Density and Subsequent Cancer Risk

NCT00340262
View directory record Official record
Conditions
Endometrial Cancer, Breast Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
55 Years to 80 Years · Female only
Enrollment
15,595 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 29, 2020 · Synced Jul 23, 2026, 2:45 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Averting Complications of Proton Pump Inhibitor Therapy by Effervescent Calcium Magnesium Citrate

NCT03812380
View directory record Official record
Conditions
Osteoporosis, Hypomagnesemia
Interventions
EffCaMgCit, Placebo
Drug · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
21 Years to 99 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 16, 2022 · Synced Jul 23, 2026, 2:45 AM EDT
Completed Early Phase 1 Interventional

High Dose Vit D Musculoskeletal Symptoms & Bone Density in Anastrozole-Treated Breast Cancer With Marginal Vit D Status

NCT00263185
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Vitamin D, Calcium carbonate, Vitamin D, Placebo
Dietary Supplement · Drug · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 21, 2014 · Synced Jul 23, 2026, 2:45 AM EDT
Completed Phase 4 Interventional

The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy

NCT00063609
View directory record Official record
Conditions
Prostate Cancer
Interventions
zoledronic acid
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
44
States / cities
Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 38 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2017 · Synced Jul 23, 2026, 2:45 AM EDT
Recruiting Phase 4 Interventional

Estrogen Supplementation and Bone Health in Women With CF

NCT05704036
View directory record Official record
Conditions
Cystic Fibrosis, Hypoestrogenism
Interventions
Transdermal estrogen, Progesterone
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
0 Years to 100 Years · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Jul 23, 2026, 2:45 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Bone Mineral Accretion in Young Children

NCT02162602
View directory record Official record
Conditions
Bone Mineral Density Reference Data
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
1 Year to 5 Years
Enrollment
484 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
2
States / cities
Cincinnati, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Jul 23, 2026, 2:45 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Bone Density and Serum Testosterone in Male Methadone Maintained Patients

NCT00170339
View directory record Official record
Conditions
Opiate Dependence, Osteoporosis, Erectile Dysfunction, Hypogonadism
Interventions
Not listed
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 13, 2016 · Synced Jul 23, 2026, 2:45 AM EDT
Completed Phase 3 Interventional Results available

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma

NCT01345019
View directory record Official record
Conditions
Cancer, Hematologic Malignancies, Multiple Myeloma, Oncology, Bone Metastases, Multiple Myeloma Bone Lesions
Interventions
Denosumab, Zoledronic acid, Placebo to Denosumab, Placebo to zoledronic acid, Denosumab (for the open-label treatment phase)
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
1,718 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
79
States / cities
Tucson, Arizona • Fayetteville, Arkansas • Anaheim, California + 67 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Jul 23, 2026, 2:45 AM EDT
Completed Not applicable Interventional

Correlation Between Vitamin D Status and Bone Mineral Density in Patients With Hemophilia

NCT01090206
View directory record Official record
Conditions
Hemophilia A, Hemophilia B, Vitamin D Deficiency
Interventions
Vitamin D and calcium
Dietary Supplement
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
2 Years to 21 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 28, 2016 · Synced Jul 23, 2026, 2:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Increased Calorie Intake to Reverse Energy Deficiency in Exercising Women: Impact on Bone and Menstrual Cyclicity

NCT00392873
View directory record Official record
Conditions
Menstrual Irregularity
Interventions
EAMD+Calories
Behavioral
Lead sponsor
Penn State University
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
233 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2014
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 7, 2017 · Synced Jul 23, 2026, 2:45 AM EDT
Recruiting Phase 3 Interventional

A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis

NCT05862272
View directory record Official record
Conditions
Uterine Fibroids, Endometriosis
Interventions
Relugolix Combination Tablet
Drug
Lead sponsor
Sumitomo Pharma Switzerland GmbH
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
120
States / cities
Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 98 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Jul 23, 2026, 2:45 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Bone Estrogen Strength Training

NCT00000399
View directory record Official record
Conditions
Osteoporosis
Interventions
Hormone replacement therapy, Strength training
Drug · Procedure
Lead sponsor
University of Arizona
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1995 – 2001
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated May 19, 2013 · Synced Jul 23, 2026, 2:45 AM EDT
Recruiting Phase 2 Interventional

Locomotor Training With Testosterone to Promote Bone and Muscle Health After Spinal Cord Injury

NCT04460872
View directory record Official record
Conditions
Spinal Cord Injury, Spinal Cord Injuries, Trauma, Nervous System, Wounds and Injury, Central Nervous System Diseases, Spinal Cord Diseases, Gonadal Disorders, Endocrine System Diseases, Hypogonadism, Genital Diseases, Male, Spinal Cord Trauma, Injuries, Spinal Cord, Walking, Difficulty, Gait Disorders, Neurologic, Locomotion Disorder, Neurologic, Wounds and Injuries, Nervous System Diseases, Testosterone Deficiency, Androgen Deficiency, Hormone Deficiency
Interventions
Testosterone Enanthate, Locomotor Training
Drug · Behavioral
Lead sponsor
North Florida Foundation for Research and Education
Other
Eligibility
18 Years and older · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Gainesville, Florida • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 5, 2025 · Synced Jul 23, 2026, 2:45 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Hormone Dynamics and Bone Mineral Density in Anorexia Nervosa v. Hypothalamic Amenorrhea

NCT00556036
View directory record Official record
Conditions
Anorexia Nervosa, Hypothalamic Amenorrhea, Obesity
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Jul 23, 2026, 2:45 AM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

Bone Development in Adolescent Girls: Effects of Calcium and Exercise

NCT00063011
View directory record Official record
Conditions
Osteoporosis
Interventions
Calcium rich diet, Weight bearing exercise
Behavioral
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
9 Years to 10 Years · Female only
Enrollment
107 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1998
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 23, 2026, 2:45 AM EDT
Terminated Phase 2 Interventional Results available

Testosterone Plus Finasteride Treatment After Spinal Cord Injury

NCT02248701
View directory record Official record
Conditions
Spinal Cord Injury, Spinal Cord Injuries, Trauma, Nervous System, Wounds and Injuries, Central Nervous System Diseases, Nervous System Diseases, Spinal Cord Diseases, Gonadal Disorders, Endocrine System Diseases, Hypogonadism, Genital Diseases, Male
Interventions
Testosterone Enanthate, Finasteride, Placebo injection, Placebo pill
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older · Male only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
2
States / cities
Gainesville, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Jul 23, 2026, 2:45 AM EDT
Completed Phase 4 Interventional Results available

Effect of Bisphosphonate on Bone Loss in Postmenopausal Women With Breast Cancer Initiating Aromatase Inhibitor Therapy

NCT00485953
View directory record Official record
Conditions
Bone Loss, Osteoporosis, Breast Cancer
Interventions
risedronate
Drug
Lead sponsor
Susan L. Greenspan
Other
Eligibility
55 Years and older · Female only
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 12, 2017 · Synced Jul 23, 2026, 2:45 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss

NCT00925600
View directory record Official record
Conditions
Cancer, Cataract, Low Bone Mineral Density, Osteopenia, Osteoporosis, Prostate Cancer
Interventions
Denosumab, Placebo
Biological
Lead sponsor
Amgen
Industry
Eligibility
30 Years to 120 Years · Male only
Enrollment
769 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
52
States / cities
Anaheim, California • Laguna Hills, California • Murrieta, California + 45 more
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Jul 23, 2026, 2:45 AM EDT
Completed Phase 3 Interventional

Prevention of Osteoporosis in Men With Prostate Cancer

NCT00048841
View directory record Official record
Conditions
Prostate Cancer, Osteoporosis, Hypogonadism
Interventions
alendronate
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
50 Years to 85 Years · Male only
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 1, 2010 · Synced Jul 23, 2026, 2:45 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Bone Modeling Effects of Combined Anabolic/Antiresorptive Administration

NCT04026256
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
Teriparatide, Denosumab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
45 Years and older · Female only
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Jul 23, 2026, 2:45 AM EDT
Active, not recruiting Phase 4 Interventional

GLP-1s to Enhance Lasting Optimal Weight

NCT06861439
View directory record Official record
Conditions
Obesity
Interventions
Tirzepatide
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
65 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Jul 23, 2026, 2:45 AM EDT
Terminated Phase 3 Interventional Results available

Multicenter,Single-arm Study to Evaluate Efficacy, Safety, & Pharmacokinetics of Denosumab in Children w/ OI

NCT02352753
View directory record Official record
Conditions
Osteogenesis Imperfecta
Interventions
Denosumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
2 Years to 17 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
13
States / cities
Los Angeles, California • Torrance, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2022 · Synced Jul 23, 2026, 2:45 AM EDT